Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its clinical trial application for 7MW3711, an antibody drug conjugate (ADC) targeting B7-H3, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of advanced solid tumors.
B7-H3 as a Target for Cancer Treatment
B7-H3 is a member of the B7 ligand family, known for its overexpression in most cancer types while being present at low levels in normal tissues. It plays a role in inhibiting tumor antigen-specific immune responses in malignant tissues, leading to primary therapeutic effects. Additionally, B7-H3 is involved in promoting tumor migration, invasion, angiogenesis, chemotherapy resistance, and altering tumor cell metabolism. 7MW3711 is designed to bind with antigens on the surface of tumor cells, enter the cells, and release small molecules through specific enzymatic hydrolysis, achieving precise tumor cell killing.
Characteristics and Efficacy of 7MW3711
7MW3711 is characterized by its stable structure, uniform composition, high purity, and ease of industrialization and amplification. Compared to similar drugs both domestically and internationally, 7MW3711 has demonstrated superior tumor killing effects across various animal tumor models. In animal safety evaluation models, including crab-eating monkeys, 7MW3711 has shown effective control of targeted and off-target toxicities, indicating its favorable drug safety and pharmacokinetic profile.-Fineline Info & Tech
